BeiGene Announces Oral Presentation and Posters at the 59th American Society of Hematology Annual Meeting
01. November 2017 09:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Nov. 01, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at the 20th Annual Meeting of CSCO
28. September 2017 09:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 28, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
BeiGene Announces Presentation at the 20th Annual Meeting of the Chinese Society of Clinical Oncology
21. September 2017 16:15 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 21, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Multiple Solid Tumors at the ESMO 2017 Congress
11. September 2017 03:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 11, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
BeiGene Initiates Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer
05. Juli 2017 07:00 ET
|
BeiGene, LTD.
BEIJING, China, and CAMBRIDGE, Mass., July 05, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing molecularly targeted and immuno-oncology...
BeiGene Presents Preliminary Phase 1 Data on BGB-A317 in Patients with Hepatocellular Carcinoma at the ESMO 19th World Congress on Gastrointestinal Cancer
29. Juni 2017 05:10 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, June 29, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and...
BeiGene Presents Initial Phase 1 Data on Anti-PD-1 Antibody BGB-A317 Combined with PARP Inhibitor BGB-290 at the 2017 American Society for Clinical Oncology Annual Meeting
05. Juni 2017 09:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass., June 05, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for...
BeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual Meeting
21. April 2017 07:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass., April 21, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for...
BeiGene Announces Initiation of First Pivotal Study in China of PD-1 Antibody BGB-A317
21. April 2017 07:00 ET
|
BeiGene, LTD.
BEIJING, April 21, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing molecularly targeted and immuno-oncology drugs for the treatment of...
BeiGene Announces First Patient Dosing in China Phase I Trial with Investigational Anti-PD-1 Monoclonal Antibody BGB-A317
30. Dezember 2016 09:00 ET
|
BeiGene, LTD.
BEIJING, Dec. 30, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of...